Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Kumar, Shaji; Kaufman, Jonathan L.; Gasparetto, Cristina; Mıkhael, Joseph; Vij, Ravi; Pegourié, Brigitte; Benboubker, Lofti; Façon, Thierry; Amiot, Martine; Moreau, Philippe; Punnoose, Elizabeth A.; Alzate, Stefanie; Dunbar, Martin; Xu, Tu; Agarwal, Suresh; Enschede, Sari H.; Leverson, Joel D.; Ross, Jeremy A.; Maciag, Paulo; Verdugo, Maria; Touzeau, Cyrille

doi:10.1182/blood-2017-06-788786

articleBloodOct 10, 2017BRONZE OA

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

SKShaji Kumar JLJonathan L. Kaufman CGCristina Gasparetto JMJoseph Mıkhael RVRavi Vij

Mayo Clinic in Arizona · Emory University · +9 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Key Points Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile in patients with relapsed/refractory MM. Venetoclax monotherapy has demonstrated antimyeloma activity in patients with relapsed/refractory MM positive for t(11;14).

Citation impact

525

total citations

FWCI: 34.31
Percentile: 100%
References: 32

Citations per year

Authors

21

Topics & keywords

Topics

Keywords

Venetoclax
Multiple myeloma
Medicine
Carfilzomib
Lenalidomide
Refractory (planetary science)
Oncology
Salvage therapy

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.